BMD SOFTWARE LDA

Their core work

BMD Software is a Portuguese software SME based in Aveiro that develops bioinformatics and biomedical data platforms. They build tools for integrating, mining, and visualizing complex biomedical datasets — from genomic data and clinical records to biophotonic images. Their work spans cancer informatics, neurodegenerative disease research, and infectious disease imaging, always contributing the software and data integration layer that makes large-scale biomedical research computationally tractable.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), BMD Software focused squarely on bioinformatics — building tools for genomic analysis, GWAS, systems medicine, and integrating clinical and molecular data for oncology and psychiatry (MedBioinformatics, EUROLEISH-NET). From 2020 onward, their work shifted toward imaging and neurodegenerative disease platforms, with IMAGE-IN bringing biophotonic image mining and EPND focusing on biomarker data for Alzheimer's and Parkinson's. The trajectory shows a company moving from text/genomic data integration toward multimodal data fusion that includes imaging alongside molecular and clinical datasets.

BMD is evolving from pure bioinformatics toward multimodal biomedical data platforms that combine imaging, genomics, and clinical data — making them increasingly relevant for precision medicine consortia.

How they like to work

BMD Software operates exclusively as a participant, never leading consortia — consistent with a specialist software provider that brings technical capability rather than scientific direction. With 66 unique partners across 18 countries in just 4 projects, they join large, international consortia (averaging 16+ partners per project). This broad network suggests they are comfortable integrating into diverse teams and adapting their software tools to varied research contexts.

Despite only four projects, BMD has built a wide network of 66 partners across 18 countries, indicating they consistently work in large pan-European consortia. Their reach is broadly European with no obvious geographic concentration beyond their Portuguese base.

What sets them apart

BMD Software occupies an uncommon niche: a private SME that builds production-grade biomedical software within academic-heavy research consortia. While most bioinformatics partners in H2020 are universities or research institutes, BMD brings a commercial software development perspective — meaning their tools are more likely to be maintained, scalable, and usable beyond the project's lifetime. For consortium builders, they offer a reliable software engineering partner who understands both the biomedical domain and the practical demands of building platforms that researchers will actually use.

Highlights from their portfolio

• IMAGE-IN
  Their largest single grant (EUR 475,440) and a shift into biophotonic imaging and data fusion — a new technical direction for the company.
• EPND
  A major European platform for neurodegenerative disorders running until 2026, positioning BMD in the high-priority Alzheimer's/Parkinson's biomarker space.
• MedBioinformatics
  Defines their core identity — integrative bioinformatics bridging cancer, CNS disorders, and systems medicine with genomic and clinical data.